🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/01/2015 156,15 157,74 151,53 151,92 -2,09% 3,98% 2.894.000
14/01/2015 152,87 155,54 152,57 155,16 +0,01% 1,94% 3.426.400
13/01/2015 158,89 160,96 153,41 155,14 -0,69% 4,75% 4.570.400
12/01/2015 156,22 157,99 154,99 156,22 +0,31% 1,92% 2.700.700
09/01/2015 158,76 158,76 154,63 155,73 -1,23% 2,60% 3.949.100
08/01/2015 159,60 162,76 155,15 157,67 -0,36% 4,77% 4.560.200
07/01/2015 154,09 158,58 153,01 158,24 +3,49% 3,61% 3.502.400
06/01/2015 158,78 158,88 152,33 152,90 -3,22% 4,13% 5.075.800
05/01/2015 157,43 159,60 154,26 157,99 -1,19% 3,39% 4.080.300
02/01/2015 160,16 162,59 158,60 159,89 +0,38% 2,49% 2.605.400
31/12/2014 161,67 163,28 159,26 159,29 -0,83% 2,49% 2.691.900
30/12/2014 162,69 162,73 160,18 160,63 -1,36% 1,57% 2.019.800
29/12/2014 163,83 164,05 161,52 162,85 -0,37% 1,54% 1.727.600
26/12/2014 162,16 164,15 161,85 163,46 +1,74% 1,42% 1.707.500
24/12/2014 156,53 163,17 156,47 160,67 +2,00% 4,28% 2.222.800
23/12/2014 164,91 164,99 154,36 157,52 -4,26% 6,45% 7.091.700
22/12/2014 168,31 169,04 163,91 164,53 -3,31% 3,05% 4.061.500
19/12/2014 168,91 171,73 167,40 170,17 +1,00% 2,56% 7.856.300
18/12/2014 166,10 168,59 164,58 168,48 +3,06% 2,41% 3.511.800
17/12/2014 159,46 164,01 158,60 163,48 +2,53% 3,39% 3.417.900
16/12/2014 157,68 163,96 157,50 159,44 -0,10% 4,10% 4.492.800
15/12/2014 164,77 164,99 159,40 159,60 -3,00% 3,39% 4.428.300
12/12/2014 163,14 167,71 162,30 164,53 -0,93% 3,32% 3.366.700
11/12/2014 166,70 169,64 165,60 166,08 +0,42% 2,42% 3.173.600
10/12/2014 169,00 169,75 165,00 165,39 -2,36% 2,81% 3.490.200
09/12/2014 170,32 170,91 167,44 169,39 -1,31% 2,04% 3.712.300
08/12/2014 169,39 173,14 169,00 171,64 +1,42% 2,44% 3.953.700
05/12/2014 166,68 169,41 166,11 169,24 +1,62% 1,98% 2.548.700
04/12/2014 167,54 168,76 166,45 166,55 -0,90% 1,38% 3.357.800
03/12/2014 169,28 169,49 166,50 168,07 -0,71% 1,77% 2.369.100